153 related articles for article (PubMed ID: 28538015)
1. The kallikrein-kinin system in diabetic kidney disease.
Liu W; Stanton RC; Zhang Z
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):351-357. PubMed ID: 28538015
[TBL] [Abstract][Full Text] [Related]
2. The role of the renal kallikrein-kinin system in diabetic nephropathy.
Riad A; Zhuo JL; Schultheiss HP; Tschöpe C
Curr Opin Nephrol Hypertens; 2007 Jan; 16(1):22-6. PubMed ID: 17143067
[TBL] [Abstract][Full Text] [Related]
3. The kallikrein-kinin system in diabetic nephropathy.
Tomita H; Sanford RB; Smithies O; Kakoki M
Kidney Int; 2012 Apr; 81(8):733-44. PubMed ID: 22318421
[TBL] [Abstract][Full Text] [Related]
4. The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney.
Phipps JA; Feener EP
Kidney Int; 2008 May; 73(10):1114-9. PubMed ID: 18272958
[TBL] [Abstract][Full Text] [Related]
5. Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice.
Desposito D; Potier L; Chollet C; Gobeil F; Roussel R; Alhenc-Gelas F; Bouby N; Waeckel L
J Pharmacol Exp Ther; 2015 Feb; 352(2):218-26. PubMed ID: 25398240
[TBL] [Abstract][Full Text] [Related]
6. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy.
Pruneau D; Bélichard P; Sahel JA; Combal JP
Curr Opin Investig Drugs; 2010 May; 11(5):507-14. PubMed ID: 20419596
[TBL] [Abstract][Full Text] [Related]
7. Local kallikrein-kinin system is involved in podocyte apoptosis under diabetic conditions.
Kwak SJ; Paeng J; Kim DH; Lee SH; Nam BY; Kang HY; Li JJ; Jung DS; Han SH; Ryu DR; Park JT; Chang TI; Yoo TH; Han DS; Kang SW
Apoptosis; 2011 May; 16(5):478-90. PubMed ID: 21373934
[TBL] [Abstract][Full Text] [Related]
8. Plasma Kallikrein-Kinin system mediates immune-mediated renal injury in trichloroethylene-sensitized mice.
Wang H; Zhang JX; Ye LP; Li SL; Wang F; Zha WS; Shen T; Wu C; Zhu QX
J Immunotoxicol; 2016 Jul; 13(4):567-79. PubMed ID: 27027470
[TBL] [Abstract][Full Text] [Related]
9. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice.
Kakoki M; Sullivan KA; Backus C; Hayes JM; Oh SS; Hua K; Gasim AM; Tomita H; Grant R; Nossov SB; Kim HS; Jennette JC; Feldman EL; Smithies O
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10190-5. PubMed ID: 20479236
[TBL] [Abstract][Full Text] [Related]
10. Enalapril treatment corrects the reduced response to bradykinin in diabetes increasing the B2 protein expression.
Rastelli VM; Oliveira MA; dos Santos R; de Cássia Tostes Passaglia R; Nigro D; de Carvalho MH; Fortes ZB
Peptides; 2008 Mar; 29(3):404-11. PubMed ID: 18190998
[TBL] [Abstract][Full Text] [Related]
11. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
12. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats.
Tschöpe C; Reinecke A; Seidl U; Yu M; Gavriluk V; Riester U; Gohlke P; Graf K; Bader M; Hilgenfeldt U; Pesquero JB; Ritz E; Unger T
Am J Physiol; 1999 Dec; 277(6):H2333-40. PubMed ID: 10600853
[TBL] [Abstract][Full Text] [Related]
13. The kallikrein-kinin system and oxidative stress.
Kayashima Y; Smithies O; Kakoki M
Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):92-6. PubMed ID: 22048723
[TBL] [Abstract][Full Text] [Related]
14. Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade.
Desposito D; Chollet C; Taveau C; Descamps V; Alhenc-Gelas F; Roussel R; Bouby N; Waeckel L
Clin Sci (Lond); 2016 Jan; 130(1):45-56. PubMed ID: 26443866
[TBL] [Abstract][Full Text] [Related]
15. The role of the kallikrein-kinin system in type I diabetes (insulitis).
Zuccollo A; Cueva F; Frontera M; Navarro M; Catanzaro O
Immunopharmacology; 1996 Jun; 33(1-3):349-50. PubMed ID: 8856183
[No Abstract] [Full Text] [Related]
16. The bradykinin system in stress and anxiety in humans and mice.
Rouhiainen A; Kulesskaya N; Mennesson M; Misiewicz Z; Sipilä T; Sokolowska E; Trontti K; Urpa L; McEntegart W; Saarnio S; Hyytiä P; Hovatta I
Sci Rep; 2019 Dec; 9(1):19437. PubMed ID: 31857655
[TBL] [Abstract][Full Text] [Related]
17. The kallikrein-kinin system.
Tang SC; Leung JCK; Lai KN
Contrib Nephrol; 2011; 170():145-155. PubMed ID: 21659767
[TBL] [Abstract][Full Text] [Related]
18. The kinin B1 receptor regulates muscle-specific E3 ligases expression and is involved in skeletal muscle mass control.
Parreiras-E-Silva LT; Reis RI; Santos GA; Pires-Oliveira M; Pesquero JB; Gomes MD; Godinho RO; Costa-Neto CM
Clin Sci (Lond); 2014 Aug; 127(3):185-94. PubMed ID: 24498923
[TBL] [Abstract][Full Text] [Related]
19. Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes.
Tschöpe C; Walther T; Yu M; Reinecke A; Koch M; Seligmann C; Heringer SB; Pesquero JB; Bader M; Schultheiss H; Unger T
Immunopharmacology; 1999 Oct; 44(1-2):35-42. PubMed ID: 10604522
[TBL] [Abstract][Full Text] [Related]
20. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.
Li HJ; Yin H; Yao YY; Shen B; Bader M; Chao L; Chao J
Cardiovasc Res; 2007 Jan; 73(1):130-42. PubMed ID: 17137568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
